FDA Approves Inebilizumab for NMOSD


The indication is just the second for a therapy treating the rare autoimmune disease.


The US Food and Drug Administration (FDA) has approved inebilizumab-cdon injection (Uplizna) for the intravenous treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with a particular antibody.

The indication makes ineblizumab, from Viela Bio, only the second therapy approved to treat the rare autoimmune disease of the central nervous system.

Patients with NMOSD suffer from their body’s immune system mistakenly attacking healthy cells and protein—primarily in the optic nerves and spinal cord. As such, they’re prone to optic neuritis, which can cause eye pain and vision loss.

Transvere myelitis—which causes numbness, weakness, or paralysis in the arms and legs—is also common in patients with NMSOD. Approximately half of all patients have permanent visual impairment and paralysis caused by such attacks.

Both women and African Americans are at a greater risk of the disease, which currently affects between 4000-8000 patients in the US.

Inebilizumab’s efficacy in treating NMOSD was demonstrated in a clinical assessment including 230 adult patients administered an intravenous form of the drug. Investigators noted 213 observed patients had antibodies against the AQP4 protein—which the disease binds to then activates other components of the immune system, causing inflammation and damage to the central nervous system.

In their 197-day trial, NMOSD relapse risk was reduced by 77% in the 161 anti-AQP4 antibody positive patients treated with inebilizumab versus placebo. Investigators observed no evidence of benefit in patients who were anti-AQP4 antibody negative.

Billy Dunn, MD, director of the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research, noted the currently limited marketed options for treating NMOSD.

"Uplizna now represents the second approved therapy for these patients within the past year,” Dunn said. “We continue to remain highly committed to the development of additional safe and effective drugs for this rare and devastating disease."

Inebilizumab received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

Related Videos
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
Sean Adrean, MD: Impact of Baseline VA on Aflibercept 8 mg Outcomes in DME | Image Credit: Linkedin
Mark Barakat, MD: Stable IOP Outcomes After Aflibercept 8 mg in DME | Image Credit: Retina Macula Institute of Arizona
How to Adequately Screen for and Treat Cognitive Decline in Primary Care
James R. Kilgore, DMSc, PhD, PA-C: Cognitive Decline Diagnostics
Roger Goldberg, MD: Impact of Dual Inhibition on Hard Exudates in DME | Image Credit: Bay Area Retina Associates
Deepayan Kar, PhD, MS: A Virtual Reality Approach to Contrast Sensitivity in AMD | Image Credit: LinkedIn
Dolly Chang, MD, PhD | Image Credit: LinkedIn
Daniel Su, MD: | Image Credit: Retina Vitreous-Associates Medical Group
Daniela Ferrara, MD, PhD: Machine Learning Predicts Functional Outcomes in DME | Image Credit: Ophthalmology Innovation Summit
© 2024 MJH Life Sciences

All rights reserved.